Evonik's Boardroom Chess: A Spurned Suitor, a Watchful Foundation, and a Stock Pricing Perfection

Evonik resists BASF's roughly EUR 10 billion approach as the RAG-Stiftung's 43.8% stake proves decisive; analysts turn more constructive.

Evonik's management isn't waiting for BASF to make the next move. According to Handelsblatt, the specialty chemicals group is actively courting investors, labor unions and political figures in a bid to preserve its independence, mounting a broad defensive campaign against a takeover from Ludwigshafen.

The pushback follows a rebuffed approach. BASF's earlier offer was valued at roughly EUR 10 billion, with Reuters putting the per-share figure at approximately EUR 22.15. Evonik's executive board dismissed the proposal as inadequate.

Whether the resistance holds may ultimately rest with a single shareholder. BASF confirmed exploratory talks with Evonik and the RAG-Stiftung about a week ago, and the stock has climbed 3.0 percent since. The foundation controls around 43.8 percent of Evonik's shares — a stake that makes its stance decisive. Without the foundation's blessing, no combination is conceivable.

A Dual Track in Düsseldorf

Friday's agenda underscores how seriously both sides are weighing their options. A BASF supervisory board committee was scheduled to discuss the situation, according to Reuters, while the RAG-Stiftung's curatorium convened on the same day. For Evonik, the calculus is delicate: management insists on charting its own course, yet the economic backdrop is tightening the screws.

The pivotal question is whether BASF will meaningfully raise its roughly EUR 10 billion benchmark. Only a formal, financially compelling bid is likely to shift the foundation's position. Running parallel is the operating picture — earnings in core businesses such as methionine set the fundamental floor for valuation. Should pricing cycles sour, management's room to fend off a rich offer over the long haul narrows accordingly.

Analysts Turn More Constructive

Market watchers have already adjusted their scorecards. Berenberg's Sebastian Bray upgraded the stock from "Sell" to "Hold" — on October 5, according to one account, and on Monday per another — lifting his price target to EUR 20. His rationale: takeover interest could establish a floor under the shares even if methionine prices weaken. Parmantier & Cie. followed on Tuesday with a "Halten" rating and a EUR 20.50 target.

The tug-of-war has left its mark on the tape. At EUR 21.24, the stock trades just below its 52-week high of EUR 21.52 — a level that already bakes in considerable M&A speculation after a sharp recovery. Investors now face a thorny question: does holding the shares still pay off given the negotiating risks?

Two Very Different Endgames

A sweetened offer would open the valuation range upward. Should BASF table an improved bid after Friday's deliberations, the stock could gain further ground, with an official offer at a meaningful premium anchoring the takeover premium in the market. Shareholders would then have a shot at additional gains driven by bidder enthusiasm or improvements in the takeover process.

The downside is equally tangible. If the courtship collapses over price differences or employee resistance, sentiment could flip abruptly. IG BCE chief Michael Vassiliadis and board member Alexander Bercht questioned a full sale of the foundation's stake in an October 7 letter to works councils. The stock has already gained 59 percent since the start of the year, and a substantial chunk of that advance rests on deal hopes. A BASF withdrawal without agreement would wipe out that premium in short order, throwing the focus back entirely onto the cyclical chemicals business — and potentially triggering steep losses.

Signals to Watch Before the Quarterly Report

Positioning now hinges on clear signals from the main players. So long as speculation about an improved BASF offer props up the price, the risk-reward skews to the upside. If talks stall or BASF ends its soundings without a bid, a sharp correction toward earlier valuation levels looms.

Meanwhile, Evonik continues to advance its operating business regardless of the takeover drama. Recent projects include a biodegradable polymer platform for drug delivery and an expansion of biotech capacity at its Fermas site in Slovakia. The next hard fundamental catalyst is already circled: on November 3, 2026, Evonik publishes its quarterly statement for the third quarter of 2026. By then, at the latest, it will become clear how well the company's own operations can sustain the current valuation without external takeover fantasy.